Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.

Liu, Steven Y.; Eary, Janet F.; Petersdorf, Stephen H.; Martin, Paul J.; Maloney, David G.; Appelbaum, Frederick R.; Matthews, Dana C.; Bush, Sharon A.; Durack, Lawrence D.; Fisher, Darrell R.; Gooley, Theodore A.; Bernstein, Irwin D.; Press, Oliver W.

doi:10.1200/jco.1998.16.10.3270

Cited by 250 publications

(104 citation statements)

References 37 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…23 The clinical results are impressive, resulting in two antibody conjugates ready for marketing approval from the FDA. RIT using HLA-DR or CD22 as targets for the radioimmunotherapy of NHL are also in earlier phases of clinical trial and the safety and efficacy of these agents is being demonstrated.…”

Section: Discussionmentioning

confidence: 99%

Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies

McDevitt

Barendswaard

et al. 2002

Leukemia

View full text Add to dashboard Cite

In recent years, radioimmunotherapy (RIT) with ␤ − particle emitting radionuclides targeting the CD20 antigen on B cells in the treatment of non-Hodgkin's lymphoma has provided the most compelling human clinical data for the success of RIT. CD19, like CD20, is an antigen expressed on the surface of cells of the B lineage, and CD19 may provide an alternative target for radioimmunotherapy of B cell neoplasms. CD19 has been largely overlooked as a target for conventional 131

show abstract

Section: Discussionmentioning

confidence: 99%

Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies

McDevitt

Barendswaard

et al. 2002

Leukemia

View full text Add to dashboard Cite

show abstract

“…Of the 21 patients given a therapeutic infusion (19 with progenitor cell rescue), 16 achieved a CR and two a PR, with 81% of patients progression free at a median follow-up of 12 months. Reporting back on long-term follow up of patients in these two trials at a median follow-up of 42 months, 12 of 39 patients remained in continuous complete remission, with those patients with indolent lymphoma gaining most from this approach (Liu et al, 1998). In terms of late toxicity, 60% of patients were found to have an elevated TSH level and two patients had developed myelodysplasia.…”

Section: Incorporation Of Rit Into Myeloablative Regimens With Progenmentioning

confidence: 99%

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Davies

2007

Oncogene

View full text Add to dashboard Cite

Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing -Y 90 ibritumomab tiuxetan and I 131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.

show abstract

“…41 With a median follow-up of 42 months, estimated overall survival (OS) and progression-free survival rates (PFS) were 68% and 42%, respectively. Toxicities were minimal when compared with conventional TBI containing transplantation regimens.…”

Section: Bone Marrow Transplantationmentioning

confidence: 99%

The use of radioimmunoconjugates in stem cell transplantation

Pagel

Matthews

Appelbaum

et al. 2002

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Radiolabeled monoclonal antibodies have been used with encouraging results in conjunction with stem cell transplantation for patients with hematologic malignancies targeting a variety of surface antigens including CD33, CD45 and CD66 for leukemias, CD20 and CD22 for non-Hodgkin's lymphomas, and ferritin for Hodgkin's disease. The results obtained targeting epithelial antigens on solid tumors, however, have generally been less encouraging, primarily due to the relative insensitivity of these malignancies to ionizing radiation. In this report we review clinical studies that have incorporated myeloablative doses of targeted radiation using radiolabeled antibodies in conjunction with stem cell transplant regimens.

show abstract

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.

Abstract: Myeloablative (131)I-anti-B1 RIT is relatively well tolerated when given with autologous stem-cell support and often results in prolonged remission durations with few late toxicities.

Cited by 250 publications

References 37 publications

Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies

Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

The use of radioimmunoconjugates in stem cell transplantation

Contact Info

Product

Resources

About